US Patent

US10857161 — Non-hormonal steroid modulators of NF-kB for treatment of disease

Method of Use · Assigned to Reveragen Biopharma Inc · Expires 2029-05-28 · 3y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition and methods for treating or reducing symptoms of muscular dystrophy using a specific compound.

USPTO Abstract

Provided herein is a pharmaceutical composition comprising a compound having the structural formula wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3747 — Agamree

Patent Metadata

Patent number
US10857161
Jurisdiction
US
Classification
Method of Use
Expires
2029-05-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Reveragen Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.